192 related articles for article (PubMed ID: 25629161)
21. ISCOMATRIX™ adjuvant promotes epitope spreading and antibody affinity maturation of influenza A H7N9 virus like particle vaccine that correlate with virus neutralization in humans.
Chung KY; Coyle EM; Jani D; King LR; Bhardwaj R; Fries L; Smith G; Glenn G; Golding H; Khurana S
Vaccine; 2015 Jul; 33(32):3953-62. PubMed ID: 26093202
[TBL] [Abstract][Full Text] [Related]
22. Broadly Reactive IgG Responses to Heterologous H5 Prime-Boost Influenza Vaccination Are Shaped by Antigenic Relatedness to Priming Strains.
Wang J; Li D; Perry S; Hilchey SP; Wiltse A; Treanor JJ; Sangster MY; Zand MS
mBio; 2021 Aug; 12(4):e0044921. PubMed ID: 34225490
[TBL] [Abstract][Full Text] [Related]
23. Safety and Immunogenicity of a Single Low Dose or High Dose of Clade 2 Influenza A(H5N1) Inactivated Vaccine in Adults Previously Primed With Clade 1 Influenza A(H5N1) Vaccine.
Winokur PL; Patel SM; Brady R; Chen WH; El-Kamary SS; Edwards K; Creech CB; Frey S; Keitel WA; Belshe R; Walter E; Bellamy A; Hill H
J Infect Dis; 2015 Aug; 212(4):525-30. PubMed ID: 25712967
[TBL] [Abstract][Full Text] [Related]
24. A cell culture-derived whole-virus H5N1 vaccine induces long-lasting cross-clade protective immunity in mice which is augmented by a homologous or heterologous booster vaccination.
Sabarth N; Savidis-Dacho H; Schwendinger MG; Brühl P; Portsmouth D; Crowe BA; Kistner O; Barrett PN; Kreil TR; Howard MK
Vaccine; 2012 Aug; 30(37):5533-40. PubMed ID: 22749797
[TBL] [Abstract][Full Text] [Related]
25. H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans.
Khurana S; Wu J; Verma N; Verma S; Raghunandan R; Manischewitz J; King LR; Kpamegan E; Pincus S; Smith G; Glenn G; Golding H
J Virol; 2011 Nov; 85(21):10945-54. PubMed ID: 21865396
[TBL] [Abstract][Full Text] [Related]
26. Comparison of single, homologous prime-boost and heterologous prime-boost immunization strategies against H5N1 influenza virus in a mouse challenge model.
Sabarth N; Howard MK; Savidis-Dacho H; van Maurik A; Barrett PN; Kistner O
Vaccine; 2010 Jan; 28(3):650-6. PubMed ID: 19896446
[TBL] [Abstract][Full Text] [Related]
27. A systematic review and meta-analysis of cross-reactivity of antibodies induced by oil-in-water emulsion adjuvanted influenza H5N1 virus monovalent vaccines.
Chada KE; Forshee R; Golding H; Anderson S; Yang H
Vaccine; 2017 May; 35(24):3162-3170. PubMed ID: 28483200
[TBL] [Abstract][Full Text] [Related]
28. Homologous and heterologous antibody responses to a one-year booster dose of an MF59(®) adjuvanted A/H5N1 pre-pandemic influenza vaccine in pediatric subjects.
Vesikari T; Forstén A; Borkowski A; Gaitatzis N; Banzhoff A; Clemens R
Hum Vaccin Immunother; 2012 Jul; 8(7):921-8. PubMed ID: 22777094
[TBL] [Abstract][Full Text] [Related]
29. A live attenuated H5N2 prime- inactivated H5N1 boost vaccination induces influenza virus hemagglutinin stalk specific antibody responses.
Kongchanagul A; Samnuan K; Wirachwong P; Surichan S; Puthavathana P; Pitisuttithum P; Boonnak K
Vaccine; 2020 Jan; 38(4):852-858. PubMed ID: 31708176
[TBL] [Abstract][Full Text] [Related]
30. Stockpiled pre-pandemic H5N1 influenza virus vaccines with AS03 adjuvant provide cross-protection from H5N2 clade 2.3.4.4 virus challenge in ferrets.
Sun X; Belser JA; Pulit-Penaloza JA; Creager HM; Guo Z; Jefferson SN; Liu F; York IA; Stevens J; Maines TR; Jernigan DB; Katz JM; Levine MZ; Tumpey TM
Virology; 2017 Aug; 508():164-169. PubMed ID: 28554058
[TBL] [Abstract][Full Text] [Related]
31. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus.
Khurana S; Chearwae W; Castellino F; Manischewitz J; King LR; Honorkiewicz A; Rock MT; Edwards KM; Del Giudice G; Rappuoli R; Golding H
Sci Transl Med; 2010 Jan; 2(15):15ra5. PubMed ID: 20371470
[TBL] [Abstract][Full Text] [Related]
32. Bacterial HA1 vaccine against pandemic H5N1 influenza virus: evidence of oligomerization, hemagglutination, and cross-protective immunity in ferrets.
Khurana S; Verma S; Verma N; Crevar CJ; Carter DM; Manischewitz J; King LR; Ross TM; Golding H
J Virol; 2011 Feb; 85(3):1246-56. PubMed ID: 21084473
[TBL] [Abstract][Full Text] [Related]
33. Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant.
Belshe RB; Frey SE; Graham I; Mulligan MJ; Edupuganti S; Jackson LA; Wald A; Poland G; Jacobson R; Keyserling HL; Spearman P; Hill H; Wolff M;
J Infect Dis; 2011 Mar; 203(5):666-73. PubMed ID: 21282194
[TBL] [Abstract][Full Text] [Related]
34. Inactivated and adjuvanted whole-virion clade 2.3.4 H5N1 pre-pandemic influenza vaccine possesses broad protective efficacy against infection by heterologous clades of highly pathogenic H5N1 avian influenza virus in mice.
Harada Y; Ninomiya-Mori A; Takahashi Y; Shirakura M; Kishida N; Kageyama T; Tada Y; Tashiro M; Odagiri T
Vaccine; 2011 Oct; 29(46):8330-7. PubMed ID: 21911027
[TBL] [Abstract][Full Text] [Related]
35. M2SR, a novel live influenza vaccine, protects mice and ferrets against highly pathogenic avian influenza.
Hatta Y; Boltz D; Sarawar S; Kawaoka Y; Neumann G; Bilsel P
Vaccine; 2017 Jul; 35(33):4177-4183. PubMed ID: 28668565
[TBL] [Abstract][Full Text] [Related]
36. Unmasking Stem-Specific Neutralizing Epitopes by Abolishing N-Linked Glycosylation Sites of Influenza Virus Hemagglutinin Proteins for Vaccine Design.
Liu WC; Jan JT; Huang YJ; Chen TH; Wu SC
J Virol; 2016 Oct; 90(19):8496-508. PubMed ID: 27440889
[TBL] [Abstract][Full Text] [Related]
37. Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults.
Schwarz TF; Horacek T; Knuf M; Damman HG; Roman F; Dramé M; Gillard P; Jilg W
Vaccine; 2009 Oct; 27(45):6284-90. PubMed ID: 19856521
[TBL] [Abstract][Full Text] [Related]
38. Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial.
Kreijtz JH; Goeijenbier M; Moesker FM; van den Dries L; Goeijenbier S; De Gruyter HL; Lehmann MH; Mutsert Gd; van de Vijver DA; Volz A; Fouchier RA; van Gorp EC; Rimmelzwaan GF; Sutter G; Osterhaus AD
Lancet Infect Dis; 2014 Dec; 14(12):1196-207. PubMed ID: 25455987
[TBL] [Abstract][Full Text] [Related]
39. The safety and immunogenicity of a MF59-adjuvanted H5N1 prepandemic influenza vaccine in healthy adults primed with homologous or heterologous H5N1 vaccines: an observational study.
Wei SH; Liu MT; Tsai YC; Liao CH; Chen CM; Wang WY; Huang YL; Chang FY; Chou P
BMC Infect Dis; 2014 Nov; 14():587. PubMed ID: 25394941
[TBL] [Abstract][Full Text] [Related]
40. Vaccination with drifted variants of avian H5 hemagglutinin protein elicits a broadened antibody response that is protective against challenge with homologous or drifted live H5 influenza virus.
Santiago FW; Fitzgerald T; Treanor JJ; Topham DJ
Vaccine; 2011 Nov; 29(48):8888-97. PubMed ID: 21963871
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
